Clinical Studies Search

Protocol Summary


Protocol No.
PSHCI-15-045
Prinicipal Investigator
McGregor, Lisa
Phase
Phase II
Age Group
Both
Scope
National
Secondary Protocol No.
ANHL12P1
Title
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Objective
Primary Aims
Tolerability
To determine the tolerability of brentuximab vedotin given in combination with
standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99).
Event Free Survival
To estimate the Event Free Survival (EFS) of Arm BV and Arm CZ and contrast these to historical control data.
Secondary Aim
MDD/MRD
To determine the prognostic significance of minimal disseminated disease (MDD)
at diagnosis and minimal residual disease (MRD) as measured by RT- polymerase chain reaction (PCR) in peripheral blood.
Applicable Disease Sites
Non-Hodgkin's Lymphoma
Status
Open
Participating Institutions
Hershey Medical Center
Contact
Name
[unknown] COG Contact
Phone No.
+1 717-531-6012